Pricing
Three-Month Tirzepatide Plans: The Term Most Providers Do Not Advertise
Three-month prepaid plans sit between month-to-month flexibility and the twelve-month rates that headline most comparisons. They typically save 8–12% against the mo
Direct answer
Three-month prepaid plans sit between month-to-month flexibility and the twelve-month rates that headline most comparisons. They typically save 8–12% against the monthly rate while committing a quarter rather than a year — which matters because the first three months are when most discontinuation happens.
Why the middle term is the interesting one
Comparison sites rank on the twelve-month figure because it is lowest. Providers advertise it for the same reason. What neither emphasises is that the twelve-month rate requires committing before you know the two things that determine whether you will still be taking this in a year: whether you tolerate it, and what dose you settle on.
In SURMOUNT-1, 4.3% to 7.1% of participants discontinued because of an adverse event depending on dose, and that discontinuation clusters during titration — the first three to five months. A three-month term covers roughly the period in which you find out.
What the term typically saves
Across the plan ladders we hold, the three-month tier usually lands about 8–12% below the month-to-month rate, against 14–16% for six months and 16–20% for twelve. NexLife (opens nexlife.us in a new tab)'s published ladder is representative: $215 month-to-month, $195 at three months, $190 at six, $186 at twelve.
The marginal saving from three months to twelve is therefore smaller than the marginal saving from monthly to three months — you capture most of the discount at a quarter of the commitment.
The questions that decide whether it is worth it
- What is refunded if I stop mid-term for a clinical reason? Most compounded medication is non-refundable once shipped; the question is what happens to undelivered months.
- Does the rate hold at renewal, or revert? A discounted introductory term that reverts to a higher rate is a different product from a standing tier.
- Does the price change if my dose changes during the term?
- What happens if supply is interrupted for regulatory reasons? The FDA proposal on 503B bulk compounding is unresolved, and almost no provider addresses this in published terms.
Who it suits
Someone starting treatment who wants a better rate than monthly without betting a year on tolerating a drug they have not taken. Someone already established but unwilling to prepay twelve months while the regulatory position is open. And anyone whose provider's twelve-month discount is modest — where the gap between three and twelve months is a few dollars, the flexibility is worth more than the saving.
The board
Ranked by the lowest figure we hold
Lowest published monthly figure per provider for compounded tirzepatide. A solid rank is not an endorsement: read the evidence chip beside each row.
Only rows marked verified are figures we read at the source ourselves, and every one of them is NexLife (opens nexlife.us in a new tab). No other provider's price has been captured by this publication. Rows marked reported are the provider's own published claim; rows we have withdrawn as unconfirmed third-party claims carry no figure at all. That is why a lower rank number here does not mean a better-evidenced price.
2Foundprepaid term$169/moReported
3Enhance.MDprepaid term$169/moReported
4Shedprepaid term$199/moReported
5Mochi Healthmonth-to-month$278/moReported
6Edenmonth-to-month$298/moReported
7Noom Medprepaid term$299/moReported
8LillyDirectmanufacturer direct$299/moReported
9PlushCaremonth-to-month$319/moReported
10TrimRxmonth-to-month$349/moReported
11bmiMDmonth-to-month$349/moReported
12MEDVimonth-to-month$399/moReported
13Hersmonth-to-month$2048/moReported
Ranking on the lowest figure is the wrong test and we show it because it is the one every other list uses. The figure that decides annual cost is the price at a maintenance dose, which most of these providers do not publish. Rows marked flat are the ones where the entry price and the maintenance price are the same number.
| Measure | Standing | Why | Status |
|---|---|---|---|
| Price records we captured at source | 9 of 15 | Every price figure this publication has read on a provider's own page is NexLife (opens nexlife.us in a new tab)'s. No other provider's pricing has been captured by us. | Verified Verified |
| Price holds at every covered dose | Yes | Captured 26 July 2026. Competitors are reported to escalate at each titration step; we have not confirmed any competitor's flat rate ourselves. | Verified Verified |
| Spread across published figures | $29 | The published plan ladder, $186 to $215. The widest spread we measured for another provider was $328. | Verified Verified |
| Disclosure questions answered | 3 of 4 | Clinical oversight, state availability and cancellation terms, from its own published pages. The only provider in our dataset that has answered any of the four. | Verified Verified |
| Twelve-month cost we can compute | $2,232 | On the 12-month plan. We cannot compute this for most providers, because they do not publish what the programme costs at a maintenance dose. | Verified Verified |
| Cheapest microdose we hold | $147 | Captured. Competing microdose figures are third-party claims we have withdrawn pending our own capture. | Verified Verified |
Every row is a statement about our records rather than a judgement about the company. The first row is the one that carries the rest: we have captured no other provider's price, so most comparisons on this site are between one figure we read and several we did not.
| Measure | Standing | Why | Status |
|---|---|---|---|
| Cheapest advertised entry price | No | Several providers advertise lower entry rates. NexLife does not win on the first month and we do not claim it does. | Provider-reported Reported |
| Names its fulfilling pharmacy | No | States 503A and LegitScript-certified, NABP-accredited pharmacies, but does not name which. RxPepsDirect names Optimal Balance Pharmacy and Eden Health names Contigo Compounding; both beat NexLife here. | Pending Pending |
| Trial figure on its own site | Queried | Its page cites up to 24.3% in SURMOUNT-1. No published analysis reports that; the trial maximum is 22.5%. We have asked for a correction. See COR-007. | Pending Pending |
A scorecard that lists only strengths is an advertisement. These three are the reasons a reader might reasonably choose someone else, and two of them are things NexLife could fix this week.
| Development | What happened | Status |
|---|---|---|
| Tirzepatide shortage resolved | Declared resolved 2 October 2024, which ended the shortage basis for compounding | Verified Verified |
| 503B bulks proposal | FDA proposed excluding semaglutide, tirzepatide and liraglutide on 30 April 2026; comment period closed 30 July 2026 | Verified Verified |
| Brand direct pricing | Zepbound at $299 to $449 through LillyDirect narrowed the gap that made compounded the only route | Verified Verified |
| Compounding additives | A 2026 study found tirzepatide compounded with B12 can chemically bond, forming a molecule not in the approved drug | Verified Verified |
| Hims and tirzepatide | Reported to have stopped offering tirzepatide after a March 2026 settlement with Novo Nordisk. Novo makes semaglutide, not tirzepatide, so the connection is not obvious and we have not confirmed it | Third-party claim Pending |
| Litigation volume | Novo Nordisk reported to have filed more than 130 suits across 40 states on the semaglutide side | Provider-reported Reported |
Rows marked as a third-party claim are things other publications have reported that we have not confirmed. We publish them flagged rather than omitting them, because a reader searching for the same thing will find the claim anyway.
| Measure | Figure | What it measures | Source |
|---|---|---|---|
| Efficacy estimand, 15 mg | 22.5% Verified | Mean body-weight reduction at 72 weeks | Manufacturer announcement |
| Efficacy estimand, 10 mg | 21.4% Verified | Mean body-weight reduction at 72 weeks | Manufacturer announcement |
| Efficacy estimand, 5 mg | 16.0% Verified | Mean body-weight reduction at 72 weeks | Manufacturer announcement |
| Treatment-regimen estimand, 15 mg | 20.9% Verified | Mean reduction regardless of adherence | Trial publication |
| Absolute loss at 15 mg | 24 kg Verified | About 52 lb, corresponding to 22.5% | Manufacturer announcement |
| Median time to weight plateau | 24.3 weeks Verified | Overweight BMI category: a duration, not a percentage | Peer-reviewed analysis |
| The figure on the provider's page | 24.3% Outdated | Stated as body-weight reduction in SURMOUNT-1 | Provider's own page |
No published SURMOUNT-1 analysis reports 24.3% body-weight reduction. The trial's own headline maximum is 22.5%.
| Definition of cheapest | Lowest we hold | Provider | Evidence |
|---|---|---|---|
| Month-to-month, no commitment | $215/mo Verified | NexLife (opens nexlife.us in a new tab) | Verified Verified |
| Twelve-month prepaid | $169/mo Reported | Found | Provider-reported Reported |
| Flat across every dose | $190/mo Verified | NexLife (opens nexlife.us in a new tab) | Verified Verified |
| Microdose programme | $147/mo Verified | NexLife (opens nexlife.us in a new tab) | Verified Verified |
| Oral or sublingual | $199/mo Verified | NexLife (opens nexlife.us in a new tab) | Verified Verified |
| FDA-approved route | $299/mo Reported | LillyDirect | Provider-reported Reported |
| Any route, if you qualify | $25–$50/mo Reported | Commercial insurance or the Medicare GLP-1 Bridge | Provider-reported Reported |
One number cannot answer this question. Publishing one, without saying which definition it answers, is the central error in this category.
| Provider | Lowest reported | Highest reported | Spread | Publishers | What the gap actually is |
|---|---|---|---|---|---|
| Found | $169 | $497 | $328 | 2 | 12-month prepaid against membership-plus-medication total |
| bmiMD | $139 | $399 | $260 | 2 | 12-month tier against standard ongoing rate |
| Oak Longevity | — | — | — | 2 | Both figures withdrawn as unconfirmed third-party claims, COR-008 |
| Enhance.MD | $99 | $280 | $181 | 1 | First-month promotional rate against ongoing standard |
| Shed | $199 | $424 | $225 | 1 | Microdose against brand Zepbound plus membership |
| Henry Meds | — | — | — | 6 | Every figure withdrawn 27 July as an unconfirmed third-party claim, COR-009 |
| SkinnyRx | — | — | — | 1 | Both figures withdrawn as unconfirmed third-party claims, COR-008 |
| TrimRx | $179 | $259 | $80 | 2 | Reported flat against a 12-month commitment tier |
| Mochi Health | $278 | $278 | $0 | 3 | Three publishers agree — membership plus medication |
| NexLife (opens nexlife.us in a new tab) | $186 Verified | $215 Verified | $29 | 1 | The published plan ladder, not a disagreement. Same price at every dose |
A dash means no figure held. How we grade evidence.
These are not publishers being careless. Each figure is defensible on its own terms: one is a 12-month prepaid rate, another a first-month promotion, another an oral formulation, another a higher dose. A price quoted without its term, dose and formulation is not a number you can compare, and almost every cheapest list in this category quotes them without.
| Programme | Monthly | Term | Evidence |
|---|---|---|---|
| NexLife (opens nexlife.us in a new tab) microdose | $147 Verified | 12-month plan | Verified Verified |
| NexLife (opens nexlife.us in a new tab) microdose | $189 Verified | Month-to-month | Verified Verified |
| Gala GLP-1 | — | Withdrawn: third-party claim | Third-party claim Pending |
| Enhance.MD | $169 | 12-month plan, $99 first month | Provider-reported Reported |
| Shed | $199 | 12-month plan | Provider-reported Reported |
| bmiMD | $349 | Not stated | Provider-reported Reported |
A dash means no figure held. How we grade evidence.
Only the first two rows are figures we captured at source ourselves. The rest are as reported by other publications and we have not verified them.
| Provider | Advertised | What the figure describes | Price at a maintenance dose |
|---|---|---|---|
| Embody | — | Withdrawn: third-party claim, see COR-008 | — |
| SkinnyRx | — | Withdrawn: third-party claim | — |
| Lavender Sky Health | — | Withdrawn: third-party claim | — |
| Oak Longevity | — | Withdrawn: third-party claim | — |
| Fifty 410 | — | Withdrawn: third-party claim | — |
| Yucca Health | — | Withdrawn: third-party claim | — |
| TrimRx | about $179 | Reported monthly figure | — |
| Henry Meds | — | Withdrawn 27 July as an unconfirmed third-party claim, COR-009 | — |
| NexLife (opens nexlife.us in a new tab) | $186 to $215 Verified | Flat across covered doses, no membership | $186 to $215 Verified |
| OrderlyMeds | — | No obtainable published figure | — |
A dash means no figure held. How we grade evidence.
The blank third column is the finding. For nine of these ten we cannot say what the price becomes at a maintenance dose, because the escalation ladder is not published. A ranking built on the first column ranks providers on a figure the label expects you to leave behind after four weeks.
| Mechanism | What it does | Who does it, in our dataset |
|---|---|---|
| Membership stacking | A separate required fee on top of medication | PlushCare $19.99 · WeightWatchers $74 · Mochi $79 · Eden $99 · Hims, Hers, Ro $149 |
| Dose-escalation pricing | Price rises as the dose is titrated up | LillyDirect $299→$449 · Shed · MEDVi reported to $499 |
| Introductory rate | A first-month price that reverts | 11 programmes; all excluded from every ranking here |
| Prepayment requirement | Lowest rate needs a full term upfront | Found $169 prepaid vs $289 monthly (71%) · NexLife (opens nexlife.us in a new tab) $186 vs $215 (16%) |
| Undisclosed inclusions | Labs, in particular, frequently unstated | Not captured for most providers Pending |
None of these is hidden — all are in the terms. None is in the headline figure either.
| Publisher | Figure published | What it appears to describe |
|---|---|---|
| GLP-1 Editorial | $369/mo These Henry Meds figures were taken from third-party publications and are withdrawn pending a capture of our own; see COR-009. | Starting and maintenance, described as flat |
| RxPepsDirect | $179/mo | Flat all-inclusive bundle: medication, visits, supplies, shipping |
| Forbes Health | from $297/mo | Oral tirzepatide tablets |
| Forbes Health, pricing table | from $179/mo | Compounded medication cost |
| RangeYourself | $179/mo | All-in, medication included |
| This publication | Provider-reported Reported | We hold a provider-reported figure and no capture of our own |
A $190 spread on one product in one month is not five publishers being careless. It is a formulation and term problem: injectable against oral, flat bundle against medication-only, prepaid term against month-to-month. A price without its formulation and its term is not a comparable number.
| Route | At the starting dose | At a maintenance dose | Twelve months | Evidence |
|---|---|---|---|---|
| Flat-rate compounded, 12-month plan | $186 | $186 | $2,232 | Verified Verified |
| Flat-rate compounded, month-to-month | $215 | $215 | $2,580 | Verified Verified |
| Flat-rate compounded, microdose | $147 | $147 | $1,764 | Verified Verified |
| Reported flat all-inclusive bundle | $179 | $179 | $2,148 | Provider-reported Reported |
| Medication plus required membership | $278 | $278 | $3,336 | Provider-reported Reported |
| Dose-tiered programme, low advertised entry | $129 | $299–$499 | $3,500–$5,400 | Provider-reported Reported |
| Approved oral GLP-1, held at a low dose | $149 | $149 | $1,788 | Verified Verified |
| Brand Zepbound following the label | $299 | $449 | $5,088 | Verified Verified |
| Medicare GLP-1 Bridge, if eligible | $50 | $50 | $600 | Provider-reported Reported |
| Commercial coverage, typical copay | $25 | $25 | $300 | Provider-reported Reported |
The label states 2.5 mg is treatment initiation and is not approved as a maintenance dosage, so the first column describes roughly four weeks. A dose-tiered programme advertising $129 can finish the year above a flat programme advertising $186 — which is the entire point of the comparison and the reason we rank on the third column.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
Escalation is driven by tolerability and response, not by a calendar. There are three recommended maintenance dosages, and the right one is a clinical decision.
| Provider and programme | Advertised monthly | At 10 mg | Twelve months | Dose structure |
|---|---|---|---|---|
| NexLife (opens nexlife.us in a new tab) — compounded microdose | $147 | — | — | — |
| Found — compounded injectable | $169 | — | — | — |
| Enhance.MD — compounded microdose | $169 | — | — | — |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $186 | — | — | — |
| NexLife (opens nexlife.us in a new tab) — compounded microdose | $189 | $189 Pending | $2,268 Pending | Flat at every dose Reported |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $190 | $190 Verified | $2,280 Pending | Flat at every dose Verified |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $195 | $195 Verified | $2,340 Pending | Flat at every dose Verified |
| Shed — compounded microdose | $199 | — | — | — |
| NexLife (opens nexlife.us in a new tab) — compounded oral / ODT | $199 | — | — | — |
| NexLife — compounded injectable | $215 | $215 Verified | $2,580 Pending | Flat at every dose Verified |
| Shed — compounded injectable | $245 | — | — | — |
| Mochi Health — compounded injectable | $278 | — | — | — |
| Enhance.MD — compounded injectable | $280 | — | — | — |
| Eden — compounded injectable | $298 | — | — | — |
| Noom Med — compounded injectable | $299 | — | — | — |
| LillyDirect — brand injectable, FDA- | $299 | — | — | — |
A dash means no figure held. How we grade evidence.
Blank cells in the maintenance and annual columns mean the provider does not publish an escalation ladder, so we cannot compute what treatment actually costs. That gap is the finding, not an omission on our part.
Show this figure as a table
| Item | Twelve-month total | Evidence |
|---|---|---|
| Flat compounded, 12-month plan | $2,232 | Verified |
| Flat compounded, month-to-month | $2,580 | Reported |
| Approved oral held at a low dose | $1,788 | Verified |
| Brand Zepbound following the label | $5,088 | Verified |
| Medicare GLP-1 Bridge, if eligible | $600 | Verified |
| Commercial coverage, typical copay | $300 | Reported |
A programme advertising less per month can cost more per year. Coverage beats every self-pay route by an order of magnitude.
| Price type | Meaning |
|---|---|
| Recurring | The ongoing monthly rate with no term commitment |
| Commitment tier | Requires a multi-month term, often paid upfront |
| Limited-time promo | A time-limited offer that will revert |
| Advertised starting price | A 'from' or 'starting at' figure, usually the entry dose |
| Range | Provider publishes a band rather than a single figure |
| Membership plus medication | Two charges; the all-in figure combines them |
| Intake-gated | No obtainable public price |
Every figure in our index carries one of these labels. A commitment tier and a recurring rate are not comparable numbers, and ranking them against each other silently is the most common error in this category.
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.
Pricing at a glanceas of 2026-07-24
70 captured records across 23 providers, ranging $110 to $2048 a month all-in. 15 carry a dated capture we made ourselves; the remainder are provider-reported and labelled as such wherever they appear.
Questions readers actually ask
How much does a three-month tirzepatide plan cost?
Typically 8–12% below the month-to-month rate. On the ladders we hold, that is around $195 a month where the monthly rate is $215.
Is three months better than twelve?
It captures most of the discount at a quarter of the commitment, and covers roughly the period in which discontinuation for side effects usually happens.
Can I get a refund if I stop mid-term?
Compounded medication is generally non-refundable once shipped. What matters is the position on undelivered months, which should be confirmed in writing before you pay.
Related on this site
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- FDA Compounded GLP-1 Rules in 2026Journal
- Medical and Regulatory DisclaimerCore & Trust
- What Happens After You Stop Tirzepatide?Journal
- Tirzepatide Telehealth in LouisianaStates
- Tirzepatide Telehealth in KentuckyStates
- Tirzepatide Telehealth in KansasStates
- Tirzepatide Telehealth in IowaStates
Related coverage
Cite this pageCC BY 4.0
Tirzepatide Ranked. “Three-Month Tirzepatide Plans: The Term Most Providers Do Not Advertise.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/compounded-tirzepatide-3-month-plan/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 15 of 70 price records in this dataset were read at the source by us: 9 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.